Please tell us about your clinical experience. How many patients with either Synovial sarcoma, myxoid/round cell liposarcoma/ Solid tumors, do you see on a yearly basis? What is the standard of care, and how do you think Afami-cel would fit in this space?

Considering that patients with myxoid liposarcomas generally have a good prognosis, with survival 72% after 10 years, and local recurrence seen only in 9% of the patients treated with limb-sparing surgery and risk-adapted radiation therapy, how big is the need for novel treatments?

For synovial sarcoma, survival rate stands at 50-60% at 5 years and 40-50% at 10 years. Recurrence has been reported up to 69 months after treatment and suggests a worse prognosis with low survival rates. What is the reason for the worse outcomes here, what are the differences in standard of care, and how likely would you be to try new treatments in patients with synovial sarcoma?

What’s your impression of the company’s entire Specific Peptide Enhanced Affinity Receptor, T-cell platform, and how can it address the needs of patients and clinicians in oncology?

How often does synovial sarcoma reappear in the same spot, or grow in new locations, within the first two to five years after surgery?

How common is the use of doxorubicin, hydrochloride and ifosfamide to reduce the number of remaining microscopic metastases? How would you assess the benefit of chemotherapy in synovial sarcoma for overall survival? What changes would you like to see in how the disease is managed? How do you see afami-cell fitting in this area?

What percent of high grade round cell LS (>5 cm), or marginally resectable tumors, are treated with pre-operative chemotherapy and/or pre-operative or post-operative radiotherapy?

How likely would you be to consider afami-cel in treatment plans in the future?